Postmenopausal osteoporosis and atheroma

Joint Bone Spine

Volumn 73, Issue 6, 2006, Pages 661-666

  Rajzbaum, Gérald ^a   Bézie, Yvonnick ^a  

^a SAINT JOSEPH HOSPITAL   (France)

Author keywords

Atherosclerosis; Fractures; Osteoporosis; Vascular calcifications

Indexed keywords

ALENDRONIC ACID; APOLIPOPROTEIN E; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; ESTRADIOL; ESTROGEN DERIVATIVE; FETUIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IBANDRONIC ACID; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPONTIN; OSTEOPROTEGERIN; PARATHYROID HORMONE[1-34]; RALOXIFENE; STATINE DERIVATIVE; VITAMIN D; WARFARIN; ANTIRHEUMATIC AGENT;

ABSORPTIOMETRY; ATHEROMA; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; DEATH; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; FEMALE; FEMUR FRACTURE; FRAGILITY FRACTURE; HUMAN; HYPERCALCEMIA; ISCHEMIA; NONHUMAN; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; SHORT SURVEY; STROKE; SYSTEMATIC REVIEW; VERTEBRA FRACTURE; ATHEROSCLEROSIS; BLOOD VESSEL; CALCINOSIS; DRUG EFFECT; PATHOLOGY; PREVALENCE; REVIEW;

ANTIRHEUMATIC AGENTS; ATHEROSCLEROSIS; BLOOD VESSELS; CALCINOSIS; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; PREVALENCE;

EID: 33845492405     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2006.02.009     Document Type: Short Survey

References (60)

1. Elkeles A. A comparative radiological study of calcified atheroma in males and females over 50 years. Lancet 2 (1957) 714-715
2. Hak A.E., Pols H.A., and van Hemert A.M. Progression of aortic calcification is associated with metacarpal bone loss during menopause. Arterioscler. Thromb. Vasc. Biol. 20 (2000) 1926-1931
3. Kiel D.P., Kauppila L.I., Cupples L.A., Hannan M.T., O'Donnell C.J., and Wilson P.W. Bone loss and the progression of abdominal aortic calcification over a 25-year period: the Framingham Heart Study. Calcif. Tissue Int. 68 (2001) 271-276
4. Frye M.A., Melton III L.J., and Bryant S.C. Osteoporosis and calcification of the aorta. Bone Miner. 19 (1992) 185-194
5. Aoyagi K., Ross P.D., Orloff J., Davis J.W., Katagiri H., and Wasnich R.D. Low bone density is not associated with aortic calcification. Calcif. Tissue Int. 69 (2001) 20-24
6. Rajzbaum G., Roger V.L., Bezie Y., Chauffert M., Breville P., Roux F., et al. French women, fractures and aortic calcifications. J. Intern. Med. 257 (2005) 117-119
7. Schulz E., Arfai K., Liu X., Sayre J., and Gilsanz V. Aortic calcification and the risk of osteoporosis and fractures. J. Clin. Endocrinol. Metab. 89 (2004) 4246-4253
8. Samelson E.J., Kiel D.P., Broe K.E., Zhang Y., Cupples L.A., Hannan M.T., et al. Metacarpal cortical area and risk of coronary heart disease: the Framingham study. Am. J. Epidemiol. 159 (2004) 589-595
9. Browner W.S., Pressman A.R., and Nevitt M.C. Association between low bone density and stroke in elderly women. The study of osteoporotic fractures. Stroke 24 (1993) 940-946
10. Laroche M., Moulinier L., Leger P., Lefebvre D., Mazieres B., and Boccalon H. Bone mineral decrease in the leg with unilateral chronic occlusive arterial disease. Clin. Exp. Rheumatol. 21 (2003) 103-106
11. Cauley J.A., Thompson D.E., Ensrud K.C., Scott J.C., and Black D. Risk of mortality following clinical fractures. Osteoporos. Int. 11 (2000) 556-561
12. Browner W.S., Seeley D.G., and Vogt T.M. Non-trauma mortality in elderly women with low bone mineral density. Study of osteoporotic fractures research group. Lancet 338 (1991) 355-358
13. Von der Recke P., Hansen M.A., and Hassager C. The association between low bone mass at the menopause and cardiovascular mortality. Am. J. Med. 106 (1999) 273-278
14. Price P.A., Buckley J.R., and Williamson M.K. The amino bisphosphonate ibandronate prevents vitamin D toxicity and inhibits vitamin D-induced calcification of arteries, cartilage, lungs and kidneys in rats. J. Nutr. 131 (2001) 2910-2915
15. Giachelli C.M., Bae N., Almeida M., Denhardt D.T., Alpers C.E., and Schwartz S.M. Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J. Clin. Invest. 92 (1993) 1686-1696
16. Bostrom K., Watson K.E., Horn S., Wortham C., Herman I.M., and Demer L.L. Bone morphogenetic protein expression in human atherosclerotic lesions. J. Clin. Invest. 91 (1993) 1800-1809
17. Shanahan C.M., Cary N.R., Metcalfe J.C., and Weissberg P.L. High expression of genes for calcification-regulating proteins in human atherosclerotic plaques. J. Clin. Invest. 93 (1994) 2393-2402
18. Hofbauer L.C., and Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 292 (2004) 490-495
19. Bucay N., Sarosi I., Dunstan C.R., Morony S., Tarpley J., Capparelli C., et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 12 (1998) 1260-1268
20. Kaden J.J., Bickelhaupt S., Grobholz R., Haase K.K., Sarikoc A., Kilic R., et al. Receptor activator of nuclear factor kappa B ligand and osteoprotegerin regulate aortic valve calcification. J. Mol. Cell. Cardiol. 36 (2004) 57-66
21. Browner W.S., Lui L.Y., and Cummings S.R. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J. Clin. Endocrinol. Metab. 86 (2001) 631-637
22. Luo G., Ducy P., and McKee M.D. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 386 (1997) 78-81
23. Plantalech L., Guillaumont M., Vergnaud P., Leclercq M., and Delmas P.D. Impairment of gamma carboxylation of circulating osteocalcin (bone gla protein) in elderly women. J. Bone Miner. Res. 6 (1991) 1211-1216
24. Yamaguchi T., Sugimoto T., Yano S., Yamauchi M., Sowa H., Chen Q., et al. Plasma lipids and osteoporosis in postmenopausal women. Endocr. J. 49 (2002) 211-217
25. Parhami F., Morrow A.D., Balucan J., Leitinger N., Watson A.D., Tintut Y., et al. Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcification in osteoporotic patients. Arterioscler. Thromb. Vasc. Biol. 17 (1997) 680-687
26. Parhami F., Tintut Y., Beamer W.G., Gharavi N., Goodman W., and Demer L.L. Atherogenic high-fat diet reduces bone mineralization in mice. J. Bone Miner. Res. 16 (2001) 182-188
27. Tanko L.B., Bagger Y.Z., Nielsen S.B., and Christiansen C. Does serum cholesterol contribute to vertebral bone loss in postmenopausal women?. Bone 32 (2003) 8-14
28. Schoofs M.W., van der Klift M., Hofman A., van Duijn C.M., Stricker B.H., Pols H.A., et al. ApoE gene polymorphisms, BMD, and fracture risk in elderly men and women: the Rotterdam study. J. Bone Miner. Res. 19 (2004) 1490-1496
29. Asou Y., Rittling S.R., and Yoshitake H. Osteopontin facilitates angiogenesis, accumulation of osteoclasts and resorption in ectopic bone. Endocrinology 142 (2001) 1325-1332
30. Matsui Y., Rittling S.R., Okamoto H., Inobe M., Jia N., Shimizu T., et al. Osteopontin deficiency attenuates atherosclerosis in female apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 1029-1034
31. Speer M.Y., McKee M.D., Guldberg R.E., Liaw L., Yang H.Y., Tung E., et al. Inactivation of the osteopontin gene enhances vascular calcification of matrix Gla protein-deficient mice: evidence for osteopontin as an inducible inhibitor of vascular calcification in vivo. J. Exp. Med. 196 (2002) 1047-1055
32. Wada T., McKee M.D., Steitz S., and Giachelli C.M. Calcification of vascular smooth muscle cell cultures: inhibition by osteopontin. Circ. Res. 84 (1999) 166-178
33. Steitz S.A., Speer M.Y., McKee M.D., Liaw L., Almeida M., Yang H., et al. Osteopontin inhibits mineral deposition and promotes regression of ectopic calcification. Am. J. Pathol. 161 (2002) 2035-2046
34. Binkert C., Demetriou M., Sukhu B., Szweras M., Tenenbaum H.C., and Dennis J.W. Regulation of osteogenesis by fetuin. J. Biol. Chem. 274 (1999) 28514-28520
35. Ketteler M., Bongartz P., Westenfeld R., Wildberger J.E., Mahnken A.H., Bohm R., et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 361 (2003) 827-833
36. Thomas T., and Martin A. Bone metabolism and energy balance: role for leptin. Joint Bone Spine 72 (2005) 471-473
37. Ducy P., Amling M., Takeda S., Priemel M., Schilling A.F., Beil F.T., et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 100 (2000) 197-207
38. Rigaux P., Benabid N., Darriet D., Delecourt C., Chieux V., and Dudermel A.F. Study of serum factors potentially involved in the pathogenesis of heterotopic bone formation after severe brain injury. Joint Bone Spine 72 (2005) 146-149
39. Thomas T., Gori F., Khosla S., Jensen M.D., Burguera B., and Riggs B.L. Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology 140 (1999) 1630-1638
40. Thomas T., Burguera B., Melton III L.J., Atkinson E.J., O'Fallon W.M., Riggs B.L., et al. Role of serum leptin, insulin, and estrogen levels as potential mediators of the relationship between fat mass and bone mineral density in men versus women. Bone 29 (2001) 114-120
41. Bonnet N., Courteix D., and Benhamou C.L. Leptin, central nervous system, and bone: influence of physical activity. Joint Bone Spine 72 (2005) 477-480
42. Parhami F., Tintut Y., Ballard A., Fogelman A.M., and Demer L.L. Leptin enhances the calcification of vascular cells: artery wall as a target of leptin. Circ. Res. 88 (2001) 954-960
43. Reilly M.P., Iqbal N., Schutta M., Wolfe M.L., Scally M., Localio A.R., et al. Plasma leptin levels are associated with coronary atherosclerosis in type 2 diabetes. J. Clin. Endocrinol. Metab. 89 (2004) 3872-3878
44. Kuro-o M., Matsumura Y., Aizawa H., Kawaguchi H., Suga T., Utsugi T., et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390 (1997) 45-51
45. Hulley S., Grady D., and Bush T. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280 (1998) 605-613
46. Rossouw J.E., Anderson G.L., Prentice R.L., Lacroix A.Z., Kooperberg C., Stefanick M.L., et al. Writing group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 288 (2002) 321-333
47. Bath P.M., and Gray L.J. Association between hormone replacement therapy and subsequent stroke: a meta-analysis. BMJ 330 (2005) 342-346
48. Niederhoffer N., Bobryshev Y.V., Lartaud-Idjouadiene I., Giummelly P., and Atkinson J. Aortic calcification produced by vitamin D3 plus nicotine. J. Vasc. Res. 34 (1997) 386-398
49. Watson K.E., Abrolat M.L., Malone L.L., Hoeg J.M., Doherty T., Detrano R., et al. Active serum vitamin D levels are inversely correlated with coronary calcification. Circulation 96 (1997) 1755-1760
50. Walsh B.W., Kuller L.H., Wild R.A., Paul S., Farmer M., Lawrence J.B., et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 279 (1998) 1445-1451
51. Barrett-Connor E., Grady D., Sashegyi A., Anderson P.W., Cox D.A., Hoszowski K., et al. MORE Investigators (Multiple Outcomes of Raloxifene Evaluation). Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE randomized trial. JAMA 287 (2002) 847-857
52. Ylitalo R. Bisphosphonates and atherosclerosis. Gen. Pharmacol. 35 (2000) 287-296
53. Price P.A., Faus S.A., and Williamson M.K. Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 817-824
54. Koshiyama H., Nakamura Y., and Tanaka S. Decrease in carotid intima-media thickness after 1 year therapy with etidronate for osteopenia associated with type 2 diabetes. J. Clin. Endocrinol. Metab. 85 (2000) 2793-2796
55. Shao J.S., Cheng S.L., Charlton-Kachigian N., Loewy A.P., and Towler D.A. Teriparatide (human parathyroid hormone (1-34) inhibits osteogenic vascular calcification in diabetic low density lipoprotein receptor-deficient mice. J. Biol. Chem. 278 (2003) 50195-50202
56. Chan M.H., Mak T.W., Chiu R.W., Chow C.C., Chan I.H., and Lam C.W. Simvastatin increases serum osteocalcin concentration in patients treated for hypercholesterolaemia. J. Clin. Endocrinol. Metab. 86 (2001) 4556-4559
57. Hsia J., Morse M., and Levin V. Effect of simvastatin on bone markers in osteopenic women: a placebo-controlled, dose-ranging trial. BMC Musculoskelet. Disord. 3 (2002) 3-7
58. Chan K.A., Andrade S.E., Boles M., Buist D.S., Chase G.A., Donahue J.G., et al. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet 355 (2000) 2185-2188
59. Meier C.R., Schlienger R.G., Kraenzlin M.E., Schlegel B., and Jick H. HMG-CoA reductase inhibitors and the risk of fractures. JAMA 283 (2000) 3205-3210
60. van Staa T.P., Wegman S., de Vries F., Leufkens B., and Cooper C. Use of statins and risk of fractures. JAMA 285 (2001) 1850-1855